Avilar Therapeutics, Inc.

Avilar Therapeutics is a biotechnology company focused on developing innovative protein degradation therapies, specifically utilizing ATACs (ASGPR Targeting Chimeras) to target extracellular proteins and address unmet medical needs in serious diseases. Founded in 2006 and headquartered in Boston, US, Avilar Therapeutics is engaged in the development of advanced protein degradation therapies. The company has completed 2 deals with its most recent funding occurring on February 10, 2023. The company raised USD 55 mn in a Seed round, with participation from investors including Astellas Venture Management, Medical Excellence Capital, RA Capital, and Sanofi Ventures.

The total amount raised to date is USD 55 mn, and the current company valuation is USD 89. 57 mn. Jesse Chen, the founder of Avilar, has a background that includes establishing other ventures in the biotechnology sector. Avilar Therapeutics specializes in the development of protein degradation therapies, focusing on a novel class of degraders known as ATACs (ASGPR Targeting Chimeras).

These products are designed to target extracellular and membrane-bound proteins, expanding the applications of protein degradation beyond traditional intracellular mechanisms. The ATACs utilize a natural endogenous process for protein degradation, aiming to address significant unmet medical needs associated with various serious diseases, given that nearly 40% of human proteins are located outside of cells. The company’s client base includes pharmaceutical and biotechnology firms seeking innovative solutions for drug development, particularly in the United States and Europe, where they aim to provide novel treatment modalities for conditions linked to extracellular proteins. Avilar Therapeutics's revenue model centers on strategic partnerships and collaborations with larger pharmaceutical companies, allowing for shared development costs and access to broader markets.

Transactions typically involve agreements for the licensing and commercialization of their proprietary ATACs, structured to include milestone payments tied to developmental progress and royalties based on product sales. The company’s flagship products, the ATACs, are positioned for impact in therapeutic markets, with potential pricing reflecting their innovative nature. Revenue is expected from collaborative agreements and royalties, rather than direct sales to consumers. In February 2023, Avilar Therapeutics raised USD 55 mn in Seed funding to advance multiple pipeline programs targeting extracellular proteins and to expand its platform of proprietary technologies.

The funding will support the design and launch of upcoming new products, although specific release dates have not been disclosed. The company is also looking to expand its reach into new markets, particularly targeting regions in Europe and Asia by 2025 to enhance their global footprint in the biotechnology sector.